To evaluate the safety and tolerability of four doses of oral vesnarinone in patients with advanced HIV disease.
Fourteen patients per dose level receive vesnarinone at 1 of 4 doses for 12 weeks. At least seven patients at a given dose level must have completed 4 weeks of treatment before dose is escalated in subsequent patients.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Masking
NONE
Enrollment
56
AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.